Literature DB >> 18218687

Vascular dysfunction in adriamycin nephrosis: different effects of adriamycin exposure and nephrosis.

Nadir Ulu1, Hendrik Buikema, Wiek H van Gilst, Gerjan Navis.   

Abstract

BACKGROUND: Nephrosis-induced endothelial dysfunction is assumed to play a main role in cardiovascular morbidity. Adriamycin-induced proteinuria is a well-established rat model for nephrotic syndrome. However, induction of nephrosis by intravenous adriamycin administration might exert direct adriamycin cardiovasculotoxicity that could obscure or modify nephrosis-induced vascular dysfunction. The present study, therefore, investigated in vitro vascular function in the isolated thoracic aorta and isolated perfused hearts of rats with adriamycin nephrosis, as compared to non-nephrotic adriamycin exposed rats.
METHODS: Adult rats received a single slow intravenous injection of either adriamycin (1.5 mg/kg, adriamycin nephrotic rats) or saline (healthy controls). In a third group of rats, the cardiovascular system, but not the kidneys, were exposed to adriamycin by transient clipping of renal arteries during adriamycin injection (adriamycin control rats).
RESULTS: Exposure of the kidneys to adriamycin induced severe proteinuria with corresponding systemic nephrosis, as apparent from hypercholesterolaemia. Adriamycin exposure of the vascular bed led to marked blunting of the aortic response to the endothelium-dependent vasodilator, acetylcholine (ACh), both in non-nephrotic and nephrotic rats. The nephrotic state reduced the bradykinin-induced increase in coronary flow and enhanced the aortic constrictor response to angiotensin II associated with reduced basal aortic NO-activity, as shown by the comparison between adriamycin nephrotic rats and healthy and adriamycin controls.
CONCLUSIONS: Vascular adriamycin exposure and nephrosis affect vascular function in a distinct and qualitatively different fashion in adriamycin-induced nephrotic syndrome. The differential effects of nephrosis and vascular adriamycin exposure have to be accounted for in the interpretation of vascular studies in adriamycin nephrosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18218687     DOI: 10.1093/ndt/gfm911

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  9 in total

1.  Tissue retention of doxorubicin and its effects on cardiac, smooth, and skeletal muscle function.

Authors:  Reid Hayward; David Hydock; Noah Gibson; Stephanie Greufe; Eric Bredahl; Traci Parry
Journal:  J Physiol Biochem       Date:  2012-08-14       Impact factor: 4.158

2.  Co-administration of resveratrol with doxorubicin in young mice attenuates detrimental late-occurring cardiovascular changes.

Authors:  Nobutoshi Matsumura; Beshay N Zordoky; Ian M Robertson; Shereen M Hamza; Nirmal Parajuli; Carrie-Lynn M Soltys; Donna L Beker; Marianne K Grant; Maria Razzoli; Alessandro Bartolomucci; Jason R B Dyck
Journal:  Cardiovasc Res       Date:  2018-08-01       Impact factor: 10.787

Review 3.  Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association.

Authors:  Umberto Campia; Javid J Moslehi; Laleh Amiri-Kordestani; Ana Barac; Joshua A Beckman; David D Chism; Paul Cohen; John D Groarke; Joerg Herrmann; Carolyn M Reilly; Neal L Weintraub
Journal:  Circulation       Date:  2019-03-26       Impact factor: 29.690

4.  Adriamycin nephropathy: a failure of endothelial progenitor cell-induced repair.

Authors:  Kaoru Yasuda; Hyeong-Cheon Park; Brian Ratliff; Francesco Addabbo; Antonis K Hatzopoulos; Praveen Chander; Michael S Goligorsky
Journal:  Am J Pathol       Date:  2010-02-18       Impact factor: 4.307

Review 5.  Exercise and Aerobic Fitness to Reduce Cancer-Related Cardiovascular Toxicity.

Authors:  Umberto Campia; Ana Barac
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-07

6.  The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice.

Authors:  Majid Ali; Marzieh Kamjoo; Huw D Thomas; Suzanne Kyle; Ivanda Pavlovska; Muhammed Babur; Brian A Telfer; Nicola J Curtin; Kaye J Williams
Journal:  Mol Cancer Ther       Date:  2011-09-16       Impact factor: 6.261

Review 7.  Animal models of cardiorenal syndrome: a review.

Authors:  Mariusz K Szymanski; Rudolf A de Boer; Gerjan J Navis; Wiek H van Gilst; Hans L Hillege
Journal:  Heart Fail Rev       Date:  2012-05       Impact factor: 4.214

8.  Effects of adriamycin and candesartan on the collagen and elastin of the aorta in rats.

Authors:  Jae-Sun Uhm; Woo-Baek Chung; Jung-Sook Yoon; Yong-Seog Oh; Ho-Joong Youn
Journal:  Clin Hypertens       Date:  2014-09-25

9.  Endothelium-dependent relaxation and angiotensin II sensitivity in experimental preeclampsia.

Authors:  Anne Marijn van der Graaf; Marjon J Wiegman; Torsten Plösch; Gerda G Zeeman; Azuwerus van Buiten; Robert H Henning; Hendrik Buikema; Marijke M Faas
Journal:  PLoS One       Date:  2013-11-06       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.